Recep Tayyip Erdoğan Üniversitesi Kurumsal Akademik Arşivi
DSpace@RTEÜ, Recep Tayyip Erdoğan Üniversitesi tarafından doğrudan ve dolaylı olarak yayınlanan; kitap, makale, tez, bildiri, rapor, araştırma verisi gibi tüm akademik kaynakları uluslararası standartlarda dijital ortamda depolar, Üniversitenin akademik performansını izlemeye aracılık eder, kaynakları uzun süreli saklar ve yayınların etkisini artırmak için telif haklarına uygun olarak Açık Erişime sunar.
Güncel Gönderiler
Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program
(Taylor and Francis Ltd., 2025) Tural, Deniz; Özkan, Oğuzcan; Mocan, Eda Eylemer; Kapar, Caner; Yaslıkaya, Şendağ; Aydın, Esra; Ürün, yüksel
Background This study evaluates the real-world efficacy and safety of avelumab maintenance therapy in patients with metastatic urothelial carcinoma (mUC) who did not progress following first-line platinum-based chemotherapy, using data from the Expanded Access Program (EAP). Patients and methods Safety and effectiveness were assessed in patients who received at least one cycle of avelumab. The primary endpoints were overall survival (OS) and progression-free survival (PFS), while secondary endpoints included safety. PFS and OS were estimated using the Kaplan-Meier method. Results The 12-month OS rate was 78% (95% CI, 74.5%-79%), with the median OS not reached. The 12-month PFS rate was 32% (95% CI, 29%-35%), and the median PFS was 5.3 months (95% CI, 3.4-7.1). Univariate analysis showed a median PFS of 2.9 months in patients with liver metastases versus 5.4 months in those without (p = 0.001), 2.8 months in patients with hemoglobin levels below 10 mg/dL versus 5.3 months in those above (p = 0.06), and 8.8 months in patients with lymph node - only metastases versus 4.1 months in patients with metastases at other sites (p = 0.05). No significant differences in PFS were observed based on chemotherapy type (cisplatin vs. carboplatin, p = 0.7), chemotherapy cycle count (<= 4 vs. > 4 cycles, p = 0.4), or first-line chemotherapy response (complete response vs. partial response/stable disease, p = 0.4). Conclusions Avelumab demonstrated efficacy and tolerability as maintenance therapy for mUC patients without progression following first-line platinum-based chemotherapy.
Two-dimensional piezoelectric nanomaterials for nanoelectronics and energy harvesting
(John Wiley and Sons Inc, 2025) Cao, Yujun; Aftab, Sikandar; Ali, Zeeshan; Khan, Muhammad Farooq; Nazir, Ghazanfar; Akman, Erdi; Li, Xin
Smart materials, especially piezoelectric materials, have gained popularity over the last two decades. Two-dimensional (2D) piezoelectric materials exhibit attributes including great flexibility, ease of workability, extensive surface area, and many active sites, indicating significant potential for future practical applications. However, 2D materials have bottlenecks such as poor stability against high-impact forces and unsatisfactory manufacturing techniques. This review examines cutting-edge research advancements on 2D piezoelectric materials and their applications in new-generation devices. First, the current review discusses the structure and working mechanism, synthesis methods, and characterization techniques of 2D piezoelectric materials. Then, a thorough review of the piezocatalysis technique is provided, analyzing the applications of 2D piezoelectric materials in various applications, including nanogenerators, nanosensors, field-effect transistors, photodetectors, and solar cells. In conclusion, the main obstacles and opportunities of 2D piezoelectric materials and their applications in the future are examined. We believe that this comprehensive review will make significant contributions to the qualitative and quantitative research of the production of commercial advanced functional devices and their large-scale integrated applications.
Epidemiology of ventilator associated events in intubated patients: a multicenter observational study
(BMC, 2025) Eryılmaz Eren, Esma; Mert, Duygu; Eser, Fatma; Şenbayrak, Seniha; Kalın, Gamze; İlgar, Tuba; Alp Meşe, Emine
BACKGROUND: Ventilator-associated infectious complications are the most prevalent healthcare-acquired infection in intensive care units. The surveillance of ventilator-associated events (VAE) has now supplanted traditional ventilator-associated pneumonia (VAP) monitoring. However, its use is not common and limited reports have been published. We aimed to describe the epidemiology, etiology and the prognosis of VAE. METHODS: This multicenter observational-descriptive study was conducted at 15 centers with active prospective surveillance of VAE. Their daily basis follow-up was for 90 days. The Centers for Disease Control and Prevention guideline 2015 update was used for the definition of VAE. VAE subdiagnosis was defined as ventilator-associated condition (VAC), infection-related ventilator-associated complication plus (IVAC-plus), infection-related ventilator-associated complications (IVAC), and possible ventilator-associated pneumonia (PVAP) RESULTS: A total of 185 VAE episodes developed in 174 of the 1018 patients included in the study. The VAE incidences per 1000 mechanical ventilation day were; VAC 2.33, IVAC-plus 6.0, IVAC 1.3 and PVAP 4.7. Additionally 158 VAP episodes (14.8%, 7.09/1000 MV days) were observed, 85 (45.9%, 4.99/1000 MV days) of them fit the definition of a concurrent VAE criteria. Risk factors for VAE included a Sequential Organ Failure Assessment (SOFA) score greater than 7 on admission (odds ratio [OR]: 1.75; 95% confidence interval [CI]: 1.23-2.47), the presence of a tracheostomy (OR:1.78; CI:1.19-2.65), and antibiotic use within the previous 90 days (OR:2.41; CI:1.09-4.20) were risk factors for VAE. The mortality rate was 59.6% in ventilated patients. Multivariate analysis identified several risk factors for mortality, as follows: age greater than 63 years (OR: 1.75; CI: 1.26-2.42), a SOFA score greater than 5 on admission (OR: 2.00; CI: 1.47-1.46), a higher mean Charlson Comorbidity Index (OR: 1.08; CI: 1.02-1.13), being a medical-type patient (OR: 1.54; CI: 1.06-2.21), healthcare-associated infections (OR: 2.01; CI: 1.39-2.88), and the occurrence of VAE (OR: 2.21; CI: 1.04-4.70). CONCLUSION: VAE is a common complication in intubated patients and is 2.21 times more likely to occur in intubated patients who die. Patients with a high SOFA score, tracheostomy and antibiotic use in the last 90 days are at increased risk. prevention of VAE in intubated patients is important for patient survival.
Variations in dentists’ thresholds for restorative treatment of active non-cavitated carious lesions: a multinational cross-sectional study
(Elsevier, 2025) Hatipoğlu, Ömer; Taha, Nessrin; Karobari, Mohmed Isaqali; Aldhelai, Thiyezen Abdullah; Ayyad, Daoud M.; Madfa, Ahmed A.; Pertek Hatipoğlu, Fatma
Objectives: To assess patterns across 21 countries in dentists’ thresholds for initiating operative treatment of active non-cavitated carious lesions and to evaluate the influence of caries risk, clinician characteristics, and geographic variation on decision-making in accordance with current guidelines. Methods: A cross-sectional, vignette-style web-based survey was conducted between June and October 2023 across 21 countries. A standardized questionnaire, comprising theoretical radiographic scenarios of occlusal and approximal active non-cavitated carious lesions at four progressive stages (E1,E2,EDJ,D1), was distributed to general dentists and specialists. Respondents selected the radiographic threshold at which they would initiate invasive treatment for patients with low and high caries risk. Guideline-concordant benchmarks were predefined as D1 for low-risk and EDJ/D1 for high-risk; any earlier choice was coded as overtreatment. Cumulative-link mixed models estimated determinants of thresholds; guideline concordance was summarized descriptively. Results: A total of 3680 dentists provided 7360 valid responses. High caries risk significantly predicted earlier intervention (occlusal OR= 0.34; approximal OR= 0.38, p < 0.001). Female dentists and restorative specialists were more conservative, while age showed no significant effect. Overall guideline adherence was low (22.7 % in low-risk and 32.7 % in high-risk scenarios). Substantial inter-country variation was observed; Bangladesh and Portugal showed highest adherence, while Kazakhstan and Colombia demonstrated overtreatment tendencies. Conclusions: Despite global promotion of minimally invasive dentistry, overtreatment of enamel lesions remains widespread. Addressing systemic, educational, and policy-level barriers is essential to improve adherence to evidence-based, risk-informed caries management. Clinical significance: This multinational study highlights substantial variability and premature intervention in caries management across countries. Identifying patterns of overtreatment and guideline discordance informs dental education and policy, emphasizing the urgent need to reinforce minimally invasive, risk-based strategies in clinical practice across participating countries.
A viral biopesticide from native Hyphantria cunea granulovirus (HycuGV) to control fall webworm (Hyphantria cunea, Drury, Lepidoptera: Arctiidae) under field conditions
(Oxford University Press, 2025) Bayramoğlu, Zeynep; Gençer, Dönüş; Saruhan, İslam; Taylan, Zeynep Şahin; Demir, İsmail
This study evaluated the efficacy and shelf life of a locally developed viral prototype product based on Hyphantria cunea granulovirus (HycuGV-Hc1) for the control of the fall webworm (Hyphantria cunea Drury; Lepidoptera: Arctiidae), a polyphagous pest commonly observed in the Black Sea and Marmara regions of Turkey, under field conditions. The field trials were conducted in Trabzon, in the Eastern Black Sea Province, during 2022 and 2023. The viral formulation was tested on mulberry, hazelnut, and walnut host plants against Hyphantria cunea larvae at 2 x 108, 2 x 107, and 2 x 106 occlusion body (OB)/ml concentrations. AGREE 50 WG (Commercial Product), which contains 50% Bacillus thuringiensis as the active ingredient used in Turkey against H. cunea was used as a comparison. At the highest concentration, the mortality rates were recorded at 85.42%, 80.85%, and 79.59% for mulberry, hazelnut, and walnut plants, respectively. When comparing the control groups across different plants, the most damage was observed on the mulberry plant. Comparable efficacy was observed with the commercial B. thuringiensis pesticide. In the shelf-life study, formulations prepared for different periods (0, 6, and 12 mo) were found to have similar mortality effects. The local viral prototype product displayed significant potential for controlling Hyphantria cunea in the field condition at 7 d after application.
